Sort publications on year
-
Pharmaco-Economics
Les patients atteints d’Alzheimer à domicile : coût et retentissement de la maladie
RIGAUD AS, BAYLE C, FORETTE F, BUTEAU L, FAGNANI F
Gérontologie ; 2001(115): 17-23
-
Pharmaco-Economics
Economic analysis of adjuvant therapy with interferon alfa 2a in stage II malignant melanoma
LAFUMA A, DRENO B, DELAUNAY M, EMERY C, FAGNANI F, HIEKE K, BONERANDI JJ, GROB JJ
Eur J Cancer ; 37(3):369-375
-
Pharmaco-Economics
Cost effectiveness of Emedastine versus Levocabastine in the Treatment of Allergic Conjunctivitis in 7 European Countries
GOUVEIA PINTO C, LAFUMA A, FAGNANI F, NUIJTEN MJC, BERDEAUX G
Pharmacoeconomics ; 19 (3): 255-265
-
Pharmaco-Economics
The contributing factors to medical cost of epilepsy: an estimation based on a French Prospective Cohort study of patients with newly diagnosed epileptic Seizures (The CAROLE study).
DE ZELICOURT M, BUTEAU L, FAGNANI F, JALLON P.
Seizure ; 2000;9(2):88-95
-
Pharmaco-Economics
Evaluation économique du dispositif transdermique de Fentanyl dans la prise en charge de la douleur cancéreuse
PECHEVIS M, EMERY C, FAGNANI F
La Lettre du Pharmacologue ; 14 (1) ; 10-14
-
Pharmaco-Economics
Economic evaluation of enoxaparin versus placebo for the prevention of venous thromboembolism in acutely ill medical patients
PECHEVIS M, DETOURNAY B, PRIBIL C, FAGNANI F, CHALANSON G
Value Health ; 2000;3(6):389-396
-
Pharmaco-Economics
Economic evaluation of enoxaparin versus heparin in unstable angina: a French sub-study of the ESSENCE trial
DETOURNAY B, HUET X, FAGNANI F, MONTALESCOT G
PharmacoEconomics ; 2020;18(1):83-89
-
Pharmaco-Economics
Coût des hospitalisations pour effet indésirable médicamenteux
DETOURNAY B, FAGNANI F, POUYANNE P, HARAMBURU F, BEGAUD B, WELSCH M, IMBS JL
Thérapie ; 2000;55:137-139
-
Pharmaco-Economics
Analyse médico-économique des thérapeutiques des condylomes acuminés externes
FAGNANI F
Ann Dermatol Venereol ; 2000;127SuppN°10: 3S27-3S29
-
Pharmaco-Economics
Ready-to-use pre-filled syringes of atropine for anaesthesia care in French hospitals – a budget impact analysis.
BENHAMOU D, PIRIOU V, DE VAUMAS C, ALBALADEJO P, MALINOVSKY JM, DOZ M, LAFUMA A, BOUAZIZ H.
Anaesth Crit Care Pain Med ; 2017;36(2);115-121
-
Pharmaco-Economics
Economie du diabète : quelles perspectives?
DETOURNAY B
Med Mal Metab ; 2018;12 (2); 190-193
-
Pharmaco-Economics
Costs associated with community acquired pneumonia in France
GRECE SABA, LUIZ FLAVIO ANDRADE, JACQUES GAILLAT, PIERRE BONNIN, CHRISTIAN CHIDIAC, HAJNAL-GABRIELA ILLES, HENRI LAURICHESSE, JONATHAN MESSIKA, JEAN-DAMIEN RICARD, BRUNO DETOURNAY, PATRICK PETITPRETZ, GERARD DE POUVOURVILLE
Eur J Health Econom ; 2018;19(4):533-544
-
Pharmaco-Economics
Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era
CACOUB P, VAUTIER M, DESBOIS AC, LAFUMA A, SAADOUN D
Liver International ; 2017:37(12):1805-1813
-
Pharmaco-Economics
Low rate of intensification in type 2 diabetic patients inadequately controlled with basal insulin: the INTERDIA study
ROUSSEL R, GOURDY P, GAUTIER JF, GUERCI B, RACCAH D, BEHAR M, ROBERT J,DETOURNAY B
Diabetes Manag ; 2016;6(6):119–127
-
Pharmaco-Economics
Conséquences économiques du suivi biologique et des complications médicales en lien avec l’utilisation des anticoagulants injectables en France.
PAUBEL P, COUSIN M, AMAR C, GOURMELEN J, FABRON C, DETOURNAY B
J Mal Vasc ; 2016;41:371-377
